Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
Sponsor: Ying Lin
Summary
This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with HRR gene mutation.
Official title: A Phase II Study of Camrelizumab, Fluzoparib and Nab-paclitaxel in Neoadjuvant Therapy of Her-2 Negative Breast Cancer Patients With HRR Gene Mutation
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
66
Start Date
2022-05-06
Completion Date
2028-12-31
Last Updated
2023-03-09
Healthy Volunteers
No
Interventions
Camrelizumab
Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle. Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle.
Fluzoparib
Fluzoparib
Nab-paclitaxel
Nab-paclitaxel
Locations (1)
First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China